Insulin icodec
- Generic Name
- Insulin icodec
- Brand Names
- Awiqli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1188379-43-2
- Unique Ingredient Identifier
- P7YU3ED05N
- Associated Conditions
- -
- Associated Therapies
- -
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 588
- Registration Number
- NCT04795531
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
🇺🇸Lakeview Clinical Research, LLC, Guntersville, Alabama, United States
🇺🇸American Clinical Trials, Buena Park, California, United States
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 526
- Registration Number
- NCT04770532
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Ternopil, Ukraine
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1085
- Registration Number
- NCT04760626
- Locations
- 🇺🇸
Cedar-Crosse Research Center, Chicago, Illinois, United States
🇬🇷Iatriko Psychicou Private Clinic, Athens, Greece
🇬🇷Korgiallenio - Benakio Hospital (Red Cross Hosp.), Athens, Greece
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT04597697
- Locations
- 🇸🇰
Summit Clinical Research s.r.o., Bratislava, Slovakia
🇨🇿Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT04582435
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT04582448
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Conditions
- Interventions
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 984
- Registration Number
- NCT04460885
- Locations
- 🇷🇺
Medinet LLC, Saint-Petersburg, Russian Federation
🇺🇸Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸Texas Diab & Endo, P.A., Round Rock, Texas, United States
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Conditions
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 205
- Registration Number
- NCT03951805
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Vic (Barcelona), Spain
A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 43
- Registration Number
- NCT03945656
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
- Conditions
- Interventions
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 154
- Registration Number
- NCT03922750
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Roma, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.